Has the Moment for CAR-T Passed?

White Paper

CAR-T and Bispecific therapies have shown promise in revolutionizing treatment for multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL). Yet, data gaps create challenges for healthcare provider (HCP) engagement and account management.

This white paper provides an in-depth analysis of the growth patterns of both therapies, highlighting key trends, challenges, and opportunities. Using CareSet’s comprehensive Medicare data, we offer critical insights into the evolution of these therapies and their impact on the healthcare landscape. Explore the shifts in the competitive landscape, the challenges with CAR-T, and the rise of Bispecific therapies.

Click here to download your copy!

Oops! Something went wrong while submitting the form.

Why is CareSet Important to your HCP Data Strategy?

Uncover the Untold: Every data point holds an untold story. Without CareSet, crucial insights from a patient’s journey or a doctor’s choice remain hidden.
See What Others Miss: Medicare is the largest closed database—CareSet tracks patient journeys across all settings. Without it, key insights from the entire care journey stay out of reach.
Unlock Hidden Opportunities: The insights others can't see are the ones that matter most. Don’t miss out on what CareSet reveals.